| First Author | Lu K | Year | 2022 |
| Journal | Cell Metab | Volume | 34 |
| Issue | 3 | Pages | 441-457.e7 |
| PubMed ID | 35235775 | Mgi Jnum | J:339137 |
| Mgi Id | MGI:7286130 | Doi | 10.1016/j.cmet.2022.02.006 |
| Citation | Lu K, et al. (2022) Defects in a liver-bone axis contribute to hepatic osteodystrophy disease progression. Cell Metab 34(3):441-457.e7 |
| abstractText | Hepatic osteodystrophy (HOD) is a metabolic bone disease that is often associated with chronic liver disease and is marked by bone loss. Here, we demonstrate that hepatic expression of the phosphatase PP2Acalpha is upregulated during HOD, leading to the downregulation of expression of the hepatokine lecithin-cholesterol acyltransferase (LCAT). Loss of LCAT function markedly exacerbates the bone loss phenotype of HOD in mice. In addition, we found that alterations in cholesterol levels are involved in the regulation of osteoblast and osteoclast activities. We also found that LCAT improves liver function and relieves liver fibrosis in the mouse HOD model by promoting reversal of cholesterol transport from the bone to the liver. In summary, defects in a liver-bone axis occur during HOD that can be targeted to ameliorate disease progression. |
